Biochemical markers for CVD risk assessment

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10267809
APP PUB NO 20160282362A1
SERIAL NO

15173852

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Provided is a method of bioassay for the quantification of N- or C-terminal neo-epitope biomarkers formed by cleavage of a CRP, ApoE, lumican, versican, perlecan, decorin, biglycan or elastin by a proteinase. The method includes contacting a biofluid sample with an antibody reactive with the neo-epitope biomarker and determining the level of binding of the antibody to the biomarker in the sample. The assay is predictive of risk of cardiovascular disease events.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
NORDIC BIOSCIENCE A/SDENMARK NORDBORG REGION SYDDANMARK

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Karsdal, Morten Copenhagen, DK 45 50
Michaelsen, Natasha Barascuk Gentofte, DK 5 16
Qvist, Per Copenhagen, DK 27 84

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Oct 23, 2026
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 23, 2030
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00